Aripiprazole Tablet
Product Images NDC 70518-0970

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-0970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Aripiprazole 5mg 70518 0970 01)

Label for Aripiprazole 5 mg oral tablets repackaged by RemedyRepack Inc. The label indicates a quantity of 30 tablets and includes barcode elements, a QR code, and packaging information. The manufacturer is listed as Amneal Pharma, Ahmedabad, India. Storage temperature guidelines and a prescription-only notice are also present.*

FDA Label Image

Mm3 (Aripiprazole 5mg 70518 0970 02)

Aripiprazole 5 mg oral tablet, single count, repackaged by RemedyRepack Inc. The label includes prescription-only designation, NDC number 70518-0970-02, manufacturer information (Amneal Pharma, Ahmedabad, India), storage instructions, and a QR code. Directions for use reference the package insert.*

FDA Label Image

Remedy Label

Label for Aripiprazole 5 mg oral tablets by RemedyRepack Inc. The label indicates a quantity of 30 tablets. It includes storage instructions, manufacturer information (Amneal Pharma, Ahmedabad, India), and a barcode with a QR code. The label specifies 'RX ONLY' and advises to see package insert for directions.*

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

Chemical structure of Aripiprazole showing its molecular components and bonds as a 2D diagram.*

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for AUC and Cmax values of Aripiprazole when combined with various drugs. The x-axis represents change relative to reference without interacting drug, with values ranging from 0.0 to 3.0. Listed interacting drugs include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others such as valproate, lithium, and lorazepam.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

A pharmacokinetic graph titled 'Effect of Other Drugs on Aripiprazole' showing fold changes in dehydro-aripiprazole levels with 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, ranging approximately from 0.0 to 3.0. Drugs listed include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others: valproate, lithium, lorazepam, with AUC and Cmax parameters shown for each.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

A chart titled 'Effect of Aripiprazole on Other Drugs' depicting fold change and 90% confidence intervals in pharmacokinetic parameters (AUC, Cmax, INR) of various drugs relative to a reference without interacting drug. The x-axis shows change relative to reference from 0.0 to 3.0, and the y-axis lists drugs including dextromethorphan, warfarin (S- and R- enantiomers), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. Points with error bars indicate minor shifts mostly near 1.0 without significant deviation.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' showing the pharmacokinetic (PK) parameters AUC and Cmax fold changes relative to reference for various special populations including CYP2D6 poor vs. extensive metabolizers, gender, age groups, hepatic impairment levels, and severe renal impairment. Error bars represent 90% confidence intervals across these categories.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

A pharmacokinetic (PK) chart displaying the fold change and 90% confidence interval (CI) of dehydro-aripiprazole levels under different conditions, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference values, and the y-axis lists specific conditions with measurements for AUC and Cmax.*

FDA Label Image

1 (Aripiprazole Tablets 7)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole (solid blue line) versus placebo (dashed red line). The graph includes numbers of subjects at risk for both groups at multiple time points along the x-axis.*

FDA Label Image

01 (Aripiprazole Tablets 8)

A Kaplan-Meier survival curve chart showing proportion with relapse over time in days from randomization, comparing Aripiprazole (solid line) versus Placebo (dashed line). The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

0102 (Aripiprazole Tablets 9)

A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over time in days from randomization for Aripiprazole versus Placebo groups. The graph includes number of subjects at risk at various time points and compares relapse rates between the two treatments over approximately 364 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.